ENGLEMAN EDGAR 4
4 · Bolt Biotherapeutics, Inc. · Filed Nov 20, 2023
Insider Transaction Report
Form 4
ENGLEMAN EDGAR
Director10% Owner
Transactions
- Sale
Common Stock
2023-11-20$0.92/sh−3,792$3,489→ 269,823 total(indirect: By Vivo Capital Surplus Fund VIII, L.P.) - Sale
Common Stock
2023-11-17$0.93/sh−8,211$7,636→ 1,981,474 total(indirect: By Vivo Capital Fund VIII, L.P.) - Sale
Common Stock
2023-11-20$0.92/sh−27,465$25,268→ 1,954,009 total(indirect: By Vivo Capital Fund VIII, L.P.) - Sale
Common Stock
2023-11-16$0.96/sh−7,531$7,230→ 1,989,685 total(indirect: By Vivo Capital Fund VIII, L.P.) - Sale
Common Stock
2023-11-17$0.93/sh−1,134$1,055→ 273,615 total(indirect: By Vivo Capital Surplus Fund VIII, L.P.) - Sale
Common Stock
2023-11-16$0.96/sh−1,040$998→ 274,749 total(indirect: By Vivo Capital Surplus Fund VIII, L.P.)
Footnotes (5)
- [F1]The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $0.95 to $0.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (4) to this Form 4.
- [F2]The securities reported herein are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. The Reporting Person is one of the voting members of Vivo Capital VIII, LLC and may be deemed to have shared voting and dispositive power over the shares held by Vivo Capital Fund VIII, L.P. The Reporting Person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein.
- [F3]The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $0.93 to $0.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (5) to this Form 4.
- [F4]The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $0.92 to $0.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (6) to this Form 4.
- [F5]The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Surplus Fund VIII, L.P. The Reporting Person is one of the voting members of Vivo Capital VIII, LLC and may be deemed to have shared voting and dispositive power over the shares held by Vivo Capital Surplus Fund VIII, L.P. The Reporting Person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein.